GRAL Stock Price, Chart, Stats & News

GRAIL Inc.
Save
2.83B
Market cap
–
Current P/E
–
Forward P/E
GRAL chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -42.52% |
Operating margin | -381.98% |
Pretax margin | -363.18% |
Net margin | -277.47% |
Effective tax rate | 23.60% |
ROA | -13.97% |
ROE | -17.11% |
D/E | 0.04x |
Interest coverage ratio | – |
GRAL valuation
P/E | – |
P/S | 13.52x |
P/B | 0.77x |
P/CF | -6.60x |
P/FCF | -6.65x |
P/OCF | -6.60x |
PEG | -1.25x |
EV multiple | -5.77x |
About
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development.
Similar securities
Based on sector and market capitalization
Report issue











